

Special Issue

Research and Clinical Application of Adenovirus (AdV)

Message from the Guest Editor

Adenovirus (AdV) is one of the most versatile viral backbones with applications ranging from gene delivery and treatment of monogenic diseases to vaccination and cancer therapy. Adenoviruses can target a broad spectrum of both dividing and non-dividing cells, do not integrate into host DNA, have high in vivo transduction capacity, and are well characterized, thereby allowing for countless modifications of their genetic structure. It is difficult to overestimate the value of AdV during the COVID-19 pandemic as, to date, AdV represents the most effective viral vector platform for anti-SARS-CoV-2 vaccines. The recent clinical successes have also demonstrated the promise of tumor-selective, infectivity-improved oncolytic adenoviruses for cancer gene therapy and highlighted their role in inducing anticancer immunity. In this Special Issue, we will discuss the most recent advances in adenovirus research and how AdV can be used to treat human diseases.

Guest Editor

Dr. Julia Davydova
Department of Surgery, University of Minnesota, Minneapolis, MN
55455, USA

Deadline for manuscript submissions

closed (15 April 2023)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/117938

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).